The purpose of this study is to determine whether anti-TSLP will decrease airway
hyperresponsiveness in patients with asthma already on daily treatment with inhaled
corticosteroids.
The investigators expect that airway hyperresponsiveness will decrease after treatment with
anti-TSLP, and that this happens due to a change in the type of mast cells with in the lungs.
Also, the investigators expect a decrease in inflammatory cells and mediators measured in
material from the lungs.
Half of the participants will receive anti-TSLP (MEDI9929) on top of their regular asthma
treatment, while the other half will receive placebo on top of their regular asthma
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Celeste Porsbjerg
Collaborators:
Lund University University of Copenhagen University of Newcastle, Australia